Latest in: Uncategorized
Featured Image

Gene therapy reimbursement status in CEE – 5/2024

As of December 2023, 10 FDA-approved gene therapies were available. Based on existing development programs, 30-50 additional gene therapies are expected to be FDA-approved by 2030. The impact on treatment outcomes but also the …
gravatar
 · 
May 13, 2024
Featured Image

FDA has approved 55 new molecules in 2023

With a focus on addressing a wide spectrum of diseases and conditions, US witnessed the most novel drug approvals in 6 years. Here we provide an overview of the key highlights in treatments that …
gravatar
 · 
January 15, 2024
Featured Image

Pharma Valuation 101: NPV vs rNPV in Drug Development

Drug development is a complex and resource-intensive process that involves significant investments in research, clinical trials, and regulatory activities. As pharmaceutical companies evaluate the potential of assets they employ various financial metrics. Two commonly …
gravatar
 · 
October 6, 2023
Featured Image

Top 3 news from ASCO 2023

American Society of Clinical Oncology (ASCO) Annual Meeting was held between the 2nd and 6th June in Chcago, USA. As the last year, here we look at the top 3 highlights we take from …
gravatar
 · 
June 13, 2023
Featured Image

ambiom presented current issues in companion diagnostics (CDx) at Central & East European Health Policy Network Oncology Workshop in Bratislava

On 1st of June 2023, the Central & East European Health Policy Network (CEE HPN) organized an oncology workshop in Bratislava, Slovakia. The workshop theme was: ,Discussion on prevention, diagnosis and treatment of oncological …
gravatar
 · 
June 6, 2023
Featured Image

HTA and MEA legislation in Ukraine: New rules in access to medical technology

The new managed entry agreement (MEA) and health technology assessment (HTA) regulations adopted in Ukraine over the course of 2020 and 2021 present significant step forward in improving access to treatment in the country. …
gravatar
 · 
May 12, 2023
Featured Image

CDx expert: “Genomics might only be the tip of the iceberg.”

It will soon be 25 years since the first CDx assay came to the market paving the way for the start of the era of personalized treatment. We have discussed the last 25 years …
gravatar
 · 
January 19, 2023

Impressum

ambiom s.r.o.
Karpatské námestie 7770/10A
831 06 Bratislava
IČO: 54219035

Contact

info@ambiom.com
+421 948 652 276

footer-FB
footer-Li
Footer-Insta

Newsletter

Back to top Arrow